Latest News about MRK
Recent news which mentions MRK
Mixed Brew: Pfizer, Merck Earnings Head Opposite Ways, But Uber And Caterpillar Slug Line Drives
August 01, 2023
From Benzinga
Merck swings to loss as it books charge on $10.8 billion acquisition of Prometheus Biosciences
August 01, 2023
From MarketWatch
The 2 Dow Stocks Everyone's Watching Tuesday Morning
August 01, 2023
From Motley Fool
Merck Swings Into Q2 Loss On Prometheus Biosciences Acquisition Charge, But Raises FY23 Revenue Outlook
August 01, 2023
Tickers
MRK
From Benzinga
Nasdaq, S&P 500 Futures Pullback After Strong July; Why This Analyst Recommends Staying Fully Invested
August 01, 2023
From Benzinga
Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda
July 31, 2023
From Benzinga
Earnings Extravaganza: Another One-Third Of S&P 500 Companies Report This Week, Including Amazon, Apple
July 31, 2023
From Benzinga
3 Pharma Stocks to Buy for Their Promising Progress
July 31, 2023
From InvestorPlace
7 Dow Stocks to Buy as Recession Fears Roll Back
July 30, 2023
From InvestorPlace
From Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
From Benzinga
Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine
July 27, 2023
Tickers
MRK
From Benzinga
Jim Cramer Recommends Holding This Health Care Stock: 'Re-Inventing Itself, Doing A Terrific Job'
July 27, 2023
From Benzinga
Individualized Cancer Treatment: Merck/Moderna's Personalized Skin Cancer Therapy Enters Late-Stage Of Development
July 26, 2023
From Benzinga
Moderna On Cathie Wood's Radar Ahead Of Q2 Results: Ark Boosts Stake In COVID-19 Vaccine Maker By $12M This Week
July 26, 2023
From Benzinga
From Benzinga
From Benzinga
Moderna Is Fairly Valued, Balancing Declining COVID-19 Base Business with Promising Future Pipeline: Analyst
July 24, 2023
From Benzinga
Dow Jones Hits Milestone: 10th Straight Day In Green, Longest Winning Streak Since Early 2017
July 21, 2023
From Benzinga
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
July 21, 2023
From MarketWatch
Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government
July 19, 2023
From Benzinga
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
July 18, 2023
From Benzinga
3 Biotech Stocks for Getting Rich in 2023
July 18, 2023
From InvestorPlace
7 Safe Stocks to Buy as Fed Gears Up for Disinflation
July 18, 2023
From InvestorPlace
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.